Combination therapy with DMARDs and biological agents in collagen- induced arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  Williams, R O ^a   Malfait, A M ^a   Butler, D M ^a   Walmsley, M J ^a   Feldmann, M ^a   Maini, R N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Animal model; Drug therapy; Monoclonal antibodies; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; INTERLEUKIN 12; MONOCLONAL ANTIBODY; OKT 4; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; DRUG POTENTIATION; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; IMMUNOTHERAPY; MICE;

EID: 0032718119     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. LORENZ HM, KALDEN JR: Biological agents in rheumatoid arthritis - Which ones could be used in combination ? Biodrugs 1998; 9: 303-24.
2. TRENTHAM DE, TOWNES AS, KANG AH: Autoimmumty to type II collagen an experimental model of arthritis. J Exp Med 1977; 146: 857-68.
3. COURTENAY JS, DALLMAN MJ, DAYAN AD, MARTIN A, MOSEDALE B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980; 283: 666-8
4. YOO TJ, KIM SY, STUART JM et al.: Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med 1988; 168: 777-82.
5. HOLMDAHL R, ANDERSSON ME, GOLDSCHMIDT TJ et al.: Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 1989; 97: 575-84.
6. TRENTHAM DE: Collagen arthritis as a relevant model for rheumatoid arthritis: Evidence pro and con. Arthritis Rheum 1982; 25: 911-6.
7. HOLMDAHL R, JANSSON L, LARSSON E, RUBIN K, KLARESKOG L: Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986; 29: 106-13.
8. BOISSIER MC, FENG XZ, CARLIOZ A, ROUDIER R, FOURNIER C: Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann Rheum Dis 1987; 46: 691-700.
9. RANGES GE, SRIRAM S, COOPER SM: Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985; 162: 1105-10.
10. HOM JT, BUTLER LD, RIEDL PE, BENDELE AM: The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur J Immunol 1988; 18: 881-8.
11. WEBB LM, WALMSLEY MJ, FELDMANN M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol 1996; 26: 2320-8.
12. MALFAIT A-M, BUTLER DM, PRESKY DH, MAINI RN, BRENNAN FM, FELDMANN M: Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998; 111: 377-83.
13. THORBECKE GJ, SHAH R, LEU CH, KURUVILLA AP, HARDISON AM, PALLADINO MA: Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89: 7375-9.
14. WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
15. PIGUET PF, GRAU GE, VESIN C, LOETSCHER H, GENTZ R, LESSLAUER W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4.
16. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α. Arthritis Rlieum 1993; 36: 1681-90.
17. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: Results of a multi-centre, randomised, double blind trial. Lancet 1994; 344: 1105-10.
18. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with a monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
19. RANKlN ECC, CHOY EHS, KASSIMOS D et al: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42.
20. SHEEHAN KC, RUDDLE NH, SCHREIBER RD: Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989; 142: 3884-93.
21. GALFRE G, MILSTEIN C, WRIGHT B: Rat X rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature 1979; 277: 131-3.
22. QIN S, COBBOLD S, TIGHE H, BENJAMIN R, WALDMANN H: CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987; 17: 1159-65.
23. COBBOLD SP, JAYASURIYA A, NASH A, PROSPERO TD, WALDMANN H: Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312: 548-51.
24. WILLIAMS RO, MASON LJ, FELDMANN M, MAINI RN: Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-6.
25. WALDMANN TA: Monoclonal antibodies in diagnosis and therapy. Science 1991; 252: 1657-62.
26. WILLIAMS RO, GHRAYEB J, FELDMANN M, MAINI RN: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84: 433-9.
27. FINCK DK, CHAN B, WOFSY D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994; 94: 585-91.
28. MAURI C, WILLIAMS RO, WALMSLEY M, FELDMANN M: Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26: 1511-8.
29. DONCARLI A, STASIUK LM, FOURNIER C, ABEHSIRA-AMAR O: Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis. Eur J Immunol 1997; 27: 1451-8.
30. BUTLER DM, MALFAIT A-M, MAINI RN, BRENNAN FM, FELDMANN M: Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen induced arthritis. Eur J Immunol 1999; 29: 2205-12.
31. YOCUM DE: Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 1996; 22: 133-54.
32. O'KEEFE SJ, TAMURA J, KINCAID RL, TOCCI MJ, O'NEILL EA: FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692-4.
33. NGUYEN DT, ESKANDAI MK, DEFORGE LE et al.: Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol 1990; 144: 3822-8.
34. WILLIAMS RO, MAURI C, MASON LJ et al.: Therapeutic actions of cyclosporin and antiTNFα in collagen-induced arthritis and effect of combination therapy. Arthritis Rheum 1998; 41: 1806-12.
35. SOMMER N, LOSCHMANN PA, NORTHOFF GH et al.: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995; 1: 244-8.
36. GENAIN CP, ROBERTS T, DAVIS RL et al.: Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995; 92: 3601-5.
37. ROSS SE, WILLIAMS RO, MASON LJ et al.: Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997; 159: 6253-9.
38. FELDMANN M, BRENNAN FM, ABNEY ER et al.: Are imbalances in cytokine function of importance in the pathogenesis of rheumatoid arthritis ? In: DAVIES ME and DINGLE JT (Eds.): Immunopharmacology of Joints and Connective Tissue. London, Academic Press, 1994: 119-28.
39. WALMSLEY M, KATSIKIS PD, ABNEY E et al.: IL-10 inhibits progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495-503.
40. TANAKA Y, OTSUKA T, HOTOKEBUCHI T et al.: Effect of IL-10 on collagen-induced arthritis in mice. Inflamm Res 1996; 45: 283-8.
41. PERSSON S, MIKULOWSKA A, NARULA S, O'GARRA A, HOLMDAHL R: Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996; 44: 607-14.
42. JOOSTEN LA, LUBBERTS E, DUREZ P et al.: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249-60.
43. KASAMA T, STRIETER RM, LUKACS NW, LINCOLN PM, BURDICK MD, KUNKEL SL: Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995; 95: 2868-76.
44. WALMSLEY M, BUTLER DM, MARINOVAMUTAFCHIEVA L, FELDMANN M: An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology 1998; 95: 31-7.
45. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis. Lancet 1999; 353: 1568-73.